Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ACADIA PHARMACEUTICALS INC. reported revenue of $1.07B, up 11.9% year over year. Operating margin was 9.8% and net margin 36.5%, on a free-cash-flow margin of 9.8% with capital expenditure at 0.4% of revenue. Every figure is computed directly from ACAD's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $1.07B | 9.8% | 36.5% |
| FY2024 | $958M | 24.1% | 23.6% |
| FY2023 | $726M | -10.1% | -8.4% |
| FY2022 | $517M | -43.2% | -41.8% |
| FY2021 | $484M | -35.2% | -34.7% |
How does ACAD compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 23 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: PG · JNJ · ABBV · BMY · ABT · AMGN
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.